Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Earle B. Barnes Award For Leadership In Chemical Research Management

by Stu Borman
January 5, 2015 | APPEARED IN VOLUME 93, ISSUE 1

Credit: NIH
Credit: NIH

Sponsored by the Dow Chemical Co. Foundation

This year’s Barnes Award honors Christopher P. Austin for “innovative management and contributions to chemical research, chemical genomics, and clinical translational sciences.” Austin is director of the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health.

His achievements include “establishing a creative research management structure and leadership that fully complements translational science at NCATS,” comments William W. Chin, executive vice president of scientific and regulatory affairs at the Pharmaceutical Research & Manufacturers of America.

“Chris’s leadership has helped establish chemistry as an essential element of NIH-led efforts toward the discovery of new therapeutics,” adds Jeffrey Aubé, professor of medicinal chemistry at the University of Kansas.

Austin helped conceive NIH’s Molecular Libraries Initiative, which developed and implemented chemical library synthesis, assays, high-throughput screening, informatics, and medicinal chemistry to promote chemical biology and drug development productivity. And he founded the NIH Chemical Genomics Center, which develops new technologies for automated screening, cheminformatics, and medicinal chemistry, and develops chemical probes in collaboration with investigators in the public and private sectors.

Together with colleagues from the National Institute of Environmental Health Sciences, the Environmental Protection Agency, and the Food & Drug Administration, Austin also founded the Toxicology in the 21st Century program, which develops molecular fingerprint data for use in computational models to predict in vivo toxicity of environmental chemicals and drugs. And he pioneered the Therapeutics for Rare & Neglected Diseases program. Scientists working in that program collaborate with academic, foundation, and biopharma investigators to develop therapeutics for patients with rare and neglected diseases. Austin’s other accomplishments at NIH include the establishment of an RNAi screening facility for NIH’s intramural research program and creation of the NCATS Pharmaceutical Collection, which catalogs all approved drugs in the U.S., Canada, Europe, and Japan.

In September 2012, Austin became the first permanent director of NCATS, which promotes innovation in translational science across the spectrum from target validation to public health, with the goal of enabling the research community to bring interventions, including diagnostics and therapeutics, to more patients more quickly.

“Chris says he is interested in not just doing translation but also studying the science of translation, a refreshing attitude that suggests he is willing to move beyond established ways of thinking about advancing potential medicines toward the clinic to address the entrenched problems that have impeded progress in the past,” Aubé says.

Austin “has organized and led units where chemistry is integrated beautifully into the science and at the highest level of quality,” Aubé adds. “He has done this by both hiring fantastic chemists and nurturing an environment where they can collaborate on contemporary approaches to difficult problems.”

Austin, 54, earned a bachelor’s degree in biology summa cum laude from Princeton University and an M.D. from Harvard Medical School. He completed clinical training in internal medicine and neurology at Massachusetts General Hospital and was a research fellow in genetics at Harvard. In 1996, he started at Merck & Co., where he served as director of Genomic Neuroscience & Genomic Pharmacology. He moved to NIH in 2002.

Austin will present the award address before the Division of Medicinal Chemistry.



This article has been sent to the following recipient:

Leave A Comment

*Required to comment